Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

OBJECTIVES: Efficacy, safety and immunogenicity results from the phase III study of SB2, a biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This transition period compared results in patients with rheumatoid arthritis (RA) who switched from INF to SB2 with those i...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ann Rheum Dis
Huvudupphovsmän: Smolen, Josef S, Choe, Jung-Yoon, Prodanovic, Nenad, Niebrzydowski, Jaroslaw, Staykov, Ivan, Dokoupilova, Eva, Baranauskaite, Asta, Yatsyshyn, Roman, Mekic, Mevludin, Porawska, Wieslawa, Ciferska, Hana, Jedrychowicz-Rosiak, Krystyna, Zielinska, Agnieszka, Lee, Younju, Rho, Young Hee
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2018
Ämnen:
Clinical and Epidemiological Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5867419/
https://ncbi.nlm.nih.gov/pubmed/29042358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2017-211741
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk